Entrada Therapeutics, Inc. (TRDA)

CIK 0001689375 · Healthcare · Biotechnology

Recent Filing Index

Form Filed Qtr End F_Period 8K: Earnings Release
Latest Q2-2026 8-K (2026-08-05) · 99.1
Q1-2026 8-K (2026-05-07) · 99.1 · 99.2
Latest FY-2025 8-K (2026-02-26) · 99.1  |  8-K (2026-01-08) · 99.1
Q3-2025 8-K (2025-11-06) · 99.1
Q2-2025 8-K (2025-08-06) · 99.1
Q1-2025 8-K (2025-05-08) · 99.1
FY-2024 8-K (2025-02-27) · 99.1  |  8-K (2025-01-15) · 99.1
Q3-2024 8-K (2024-11-05) · 99.1
Q2-2024 8-K (2024-08-13) · 99.1
Q1-2024 8-K (2024-05-07) · 99.1
FY-2023 8-K (2024-03-13) · 99.1
Q3-2023 8-K (2023-11-07) · 99.1
Q1-2023
FY-2022

Filing Summary

Report Name | Notes Fiscal Period (Annual) Fiscal Period (Quarter)
Cover Page
Audit Information
—
Statements
Consolidated Balance Sheets
Consolidated Balance Sheets (P)
Consolidated Statements of Operations and Comprehensive Loss
Condensed Consolidated Statements Stockholders Equity
—
Consolidated Statements of Operations and Comprehensive Income (loss)
Consolidated Statements of Stockholders Equity
Consolidated Statements of Cash Flows
Consolidated Statements of Operations and Comprehensive Income (loss) (P)
—
Consolidated Statements of Operations and Comprehensive Loss (P)
—
Consolidated Statements of Stockholders Equity (P)
Notes
Accrued Expenses and Other Current Liabilities
Cash, Cash Equivalents and Restricted Cash
—
Collaboration and License Agreements
Commitments and Contingencies
Common Stock and Preferred Stock
Cybersecurity Risk Management and Strategy Disclosure
—
Employee Benefit Plan
—
Fair Value Measurements
Income Taxes
Insider Trading Arrangements
Insider Trading Policies and Procedures
—
Leases
Marketable Securities
Nature of The Business
Net (loss) Income Per Share
—
Net Income (loss) Per Share
Net Loss Per Share
Pay Vs Performance Disclosure
Property and Equipment, Net
Segment Information
Stock Based Compensation
—
Stock-based Compensation
Subsequent Events
Summary of Significant Accounting Policies